Dexilant / Dexlansoprazole
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Igalmi / Dexmedetomidine
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Nuedexta / Dextromethorphan hydrobromide and quinidine sulfate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cambia / Diclofenac potassium
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Norpace / Norpace CR / Disopyramide phosphate
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Depakote / Divalproex sodium
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tikosyn / Dofetilide
Dose or interval change · Cockcroft-Gault CrCl with actual body weight, mL/min
Local official-label summary. Read the exact source scope and cautions.
Silenor / Doxepin hydrochloride
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Ocella / Drospirenone and ethinyl estradiol
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Trulicity / Dulaglutide
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Imfinzi / Durvalumab
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Avodart / Dutasteride
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Savaysa / Edoxaban tosylate
Restriction or avoidance · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
Sustiva / Efavirenz
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
SYMFI / Efavirenz, lamivudine and tenofovir disoproxil fumarate
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Zepatier / Elbasvir and grazoprevir
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Empliciti / Elotuzumab
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Stribild / Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Hemlibra / Emicizumab-kxwh
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Trijardy XR / Empagliflozin, linagliptin, metformin hydrochloride
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Vasotec / Enalapril maleate
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Enalaprilat
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lovenox / Enoxaparin sodium
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Rozlytrek / Entrectinib
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Epkinly / Epcoritamab-bysp
Pharmacokinetics only · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Aimovig / Erenumab-aooe
Evidence gap · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Segluromet / Ertugliflozin and metformin hydrochloride
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Steglujan / Ertugliflozin and sitagliptin
Restriction or avoidance · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lexapro / Escitalopram
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Nexium / Esomeprazole magnesium
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Lunesta / Eszopiclone
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Intelence / Etravirine
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Afinitor / Everolimus
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Famvir / Famciclovir
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Trilipix / Fenofibric acid
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Dificid / Fidaxomicin
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details